Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others

Publisher: La Merie Publishing
Pages: 117
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0159
Release Date: December of 2016

700.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others

This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others evaluates as of December 2016 the competitive field of mainly inhibitors and antagonists of substrates, enzymes and receptors involved in the immunosuppressive tumor microenvironment, including

  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-β/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4)
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 – SIRPα (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase)

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

More than 45 new  molecular entities modulating the immunosuppressive tumor microenvironment are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further eight molecules are undergoing IND-enabling studies.

The report includes a compilation of currently active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others

Table of Contents

1) IDO & TDO Inhibitors

  • Epacadostat Studies
  • Indoximod Studies
  • Novel IDO Inhibitors
  • Novel TDO Inhibitors
  • Dual IDO & TDO Inhibitors

2) TGF-beta/R Inhibitors

3) CXCR4 Antagonists & CXCL12 Inhibitors

4) CSF-1R Antagonists & CSF-1R tk Inhibitors

5) CD47 – SIRPα Pathway Inhibition

6) Adenosine Pathway

  • Adenosine A2 Receptor (A2AR) Antagonists
  • CD73 (AMPase) & CD39 (ATP/ADPase) Inhibitors and Adenosine Degradation

7) STING Receptor Stimulators

8) Other Inhibitors of Immunosuppressive Tumor Microenvironment

9) Corporate Tumor Microenvironment Modulator R&D Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top